The Reproductive Infectious Diseases Program is a network of health professionals, researchers and knowledge users dedicated to advancing reproductive infectious diseases care and research internationally. Through local, national and global research collaborations, the team works to address emergent knowledge gaps and provide evidence-based guidance for the prevention, treatment, and care of reproductive infectious diseases. An overview of the program and the research we do can be found here. 

Latest Updates from the RID Program:

...

New Publication: “Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study” published in Vaccine!

A new publication authored by RID Program team members Dr. Elisabeth McClymont, Dr. Chelsea Elwood, and Dr. Deborah Money as well as other longstanding RID Program collaborators is currently in press in the journal Vaccine (Journal of the Japanese Society of Vaccinology) and will be published in the upcoming issue of the journal.

This publication describes findings from the first iteration of the COVERED Project’s Immune Sub-Study. Click here to access the publication!

...

RID Program 2023 Annual Report is Now Available!

The RID Program has released its annual report on the activities conducted by the research team in 2023!

Click here to access the report and learn about all of the amazing work completed, conferences attended, new publications and other important accomplishments for the RID Program in 2023, as well as updates on our ongoing research projects.

Highlighted Research

NOVA-HIV

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV

The goal of this study is to explore reduced dosing of the nonavalent HPV vaccine in women living with HIV. This multi-site phase IV clinical trial will carry on from our previous HPV in HIV studies. Recruitment began in late 2023 and is currently ongoing.

Antenatal Serostudies

Canadian Population Serological Survey Utilizing Antenatal Serum Samples

This national project will improve our understanding of the seroprevalence of antibodies to SARS-CoV-2 using antenatal blood samples which are routinely taken as part of prenatal care. Pregnant women are representative of generally healthy adults from ages 18-45 years from all socioeconomic and cultural backgrounds; use of these existing samples will provide a window into the generally healthy adult population of Canada as a whole.

COVERED Vaccine Registry

Canadian COVID-19 Vaccine Registry for Pregnant and Lactating Individuals (COVERED)

The goal of this program is to monitor the attitudes, safety and effectiveness of the various vaccines for those who are pregnant and lactating. Through this survey, we will document vaccine safety for those who are pregnant and lactating. This project is endorsed by COVID-19 Immunity Task Force and funded by Public Health Agency of Canada.